Compounds inhibiting the activation of the nuclear factor B (NF-B)
are used for the preparation of medications adapted for the treatment of malignant
hemopathies and solid tumors, and for the prevention of the appearance or the treatment,
of phenomena of resistance to cytotoxic molecules used in the scope of treatment
of the above pathologies, appearing in patients treated with these molecules when
the latter are adapted to activate NF-B.
